Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Pfizer Ltd. Ramsgate Road, Sandwich, Kent CT13 9NJ, UK
Woman and Man Max 99 years
Pfizer Ltd. Ramsgate Road, Sandwich, Kent CT13 9NJ, UK
Update Il y a 4 ans
A PHASE 2, 12 WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED, PARALLEL GROUP, PROOF OF CONCEPT STUDY EVALUATING THE EFFICACY AND SAFETY OF PD 0299685 FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH INTERSTITIAL CYSTITIS/PAINFUL BLADDER SYNDROME
To assess the efficacy of PD 0299685 in the treatment of symptoms associated with interstitial cystitis/painful bladder syndrome including bladder pain, urinary urgency and frequency.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Pfizer Ltd. Ramsgate Road, Sandwich, Kent CT13 9NJ, UK
Update Il y a 4 ans
A 6-MONTH, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER, PARALLEL GROUP, MAINTENANCE OF EFFECT STUDY OF ESREBOXETINE (PNU-165442G) ADMINISTERED ONCE DAILY (QD) IN PATIENTS WITH FIBROMYALGIA
To evaluate the efficacy of ESRBX (QD) compared with placebo treatment in assessing the maintenance of effect for the treatment of pain intensity and function associated with fibromyalgia.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Pfizer Ltd. Ramsgate Road, Sandwich, Kent CT13 9NJ, UK
Update Il y a 4 ans
A two-year multi-centre, randomized two arm study of Genotropin treatment in very young children born small for gestational age: Early Growth and Neurodevelopment (EGN)
The primary objective of this trial is to evaluate the efficacy of Genotropin® treatment on height velocity SDS in short SGA children starting treatment at an age of 24-30 months as compared to untrea...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Pfizer Ltd. Ramsgate Road, Sandwich, Kent CT13 9NJ, UK
Update Il y a 4 ans
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVALUATE EFFICACY AND SAFETY OF CP-945,598 IN SUBJECTS WITH NON-ALCOHOLIC STEATOHEPATITIS
To evaluate the efficacy of 20 mg QD and 5 mg QD of CP-945,598 given for 48 weeks in the treatment of NASH.
Country
None
organs
None
Specialty
None
Closed trial
More information
Man Max 99 years
Pfizer Ltd. Ramsgate Road, Sandwich, Kent CT13 9NJ, UK
Update Il y a 4 ans
A PHASE 2, 16 WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED, PARALLEL GROUP PROOF-OF-CONCEPT STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF PAIN ASSOCIATED WITH CHRONIC ABACTERIAL PROSTATITIS
To evaluate the efficacy, safety and tolerability of a single intravenous infusion of tanezumab in the treatment of pain associated with chronic prostatitis.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Pfizer Ltd. Ramsgate Road, Sandwich, Kent CT13 9NJ, UK
Update Il y a 4 ans
A PHASE 2A RANDOMIZED DOUBLE-BLINDED, PLACEBO AND ACTIVE CONTROLLED TWO COHORT TWO DOSES CROSS-OVER MULTI-CENTER CLINICAL STUDY TO ASSESS EFFICACY OF A ONCE DAILY ADMINISTRATION OF A PHOSPHODIESTERASE 5 INHIBITOR (PF-00489791) FOR THE TREATMENT OF VASOSPASM IN PRIMARY AND SECONDARY RAYNAUD’S PHENOMENON
The primary objective of this study is to evaluate the efficacy of different doses of PF-00489791 on the Raynaud’s Condition Score (RCS) in PRP and SRP patients.
Country
None
organs
None
Specialty
None
Closed trial
More information